Claro Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.86M | Sell |
23,282
-108
| -0.5% | -$23.2K | 0.61% | 31 |
|
|
2026
Q1 | $5.09M | Buy |
23,390
+1,861
| +9% | +$413K | 0.61% | 35 |
|
|
2025
Q4 | $4.92M | Buy |
21,529
+269
| +1% | +$61.3K | 0.67% | 30 |
|
|
2025
Q3 | $4.92M | Buy |
21,260
+208
| +1% | +$42.4K | 0.72% | 29 |
|
|
2025
Q2 | $3.91M | Sell |
21,052
-1,568
| -7% | -$291K | 0.65% | 33 |
|
|
2025
Q1 | $4.74M | Sell |
22,620
-480
| -2% | -$93.3K | 0.63% | 25 |
|
|
2024
Q4 | $4.1M | Sell |
23,100
-1,629
| -7% | -$300K | 0.55% | 32 |
|
|
2024
Q3 | $4.88M | Buy |
24,729
+1,433
| +6% | +$267K | 0.63% | 29 |
|
|
2024
Q2 | $4M | Sell |
23,296
-666
| -3% | -$110K | 0.62% | 30 |
|
|
2024
Q1 | $4.36M | Buy |
23,962
+363
| +2% | +$62.6K | 0.76% | 29 |
|
|
2023
Q4 | $3.66M | Sell |
23,599
-1,802
| -7% | -$263K | 0.79% | 25 |
|
|
2023
Q3 | $3.79M | Buy |
25,401
+1,583
| +7% | +$232K | 0.95% | 18 |
|
|
2023
Q2 | $3.21M | Buy |
23,818
+7,357
| +45% | +$1.08M | 0.8% | 24 |
|
|
2023
Q1 | $2.62M | Sell |
16,461
-269
| -2% | -$41.1K | 0.77% | 21 |
|
|
2022
Q4 | $2.7M | Buy |
16,730
+1,352
| +9% | +$207K | 0.88% | 21 |
|
|
2022
Q3 | $2.35M | Hold |
15,378
| – | – | 0.94% | 22 |
|
|
2022
Q2 | $2.35M | Buy |
15,378
+3,642
| +31% | +$557K | 0.94% | 22 |
|
|
2022
Q1 | $1.59M | Hold |
11,736
| – | – | 0.57% | 37 |
|
|
2021
Q4 | $1.59M | Buy |
11,736
+1,001
| +9% | +$118K | 0.57% | 37 |
|
|
2021
Q3 | $1.16M | Buy |
10,735
+1,336
| +14% | +$153K | 0.49% | 49 |
|
|
2021
Q2 | $1.06M | Buy |
9,399
+186
| +2% | +$20.9K | 0.48% | 50 |
|
|
2021
Q1 | $997K | Buy |
9,213
+1,004
| +12% | +$107K | 0.51% | 50 |
|
|
2020
Q4 | $880K | Sell |
8,209
-669
| -8% | -$64.3K | 0.47% | 58 |
|
|
2020
Q3 | $778K | Sell |
8,878
-206
| -2% | -$19.4K | 0.49% | 51 |
|
|
2020
Q2 | $892K | Buy |
9,084
+1,606
| +21% | +$141K | 0.61% | 35 |
|
|
2020
Q1 | $570K | Buy |
7,478
+4,066
| +119% | +$346K | 0.53% | 54 |
|
|
2019
Q4 | $302K | Buy |
3,412
+34
| +1% | +$2.82K | 0.23% | 117 |
|
|
2019
Q3 | $256K | Sell |
3,378
-670
| -17% | -$45.9K | 0.23% | 130 |
|
|
2019
Q2 | $294K | Sell |
4,048
-262
| -6% | -$20.6K | 0.27% | 118 |
|
|
2019
Q1 | $347K | Buy |
4,310
+1,457
| +51% | +$119K | 0.34% | 90 |
|
|
2018
Q4 | $270K | Buy |
+2,853
| New | +$251K | 0.22% | 101 |
|
Other funds holding ABBV
Claro Advisors's ABBV Position: Q2 2026 in Review
Claro Advisors reduced its AbbVie (ABBV) stake by 0.46% in Q2 2026, selling an estimated $23.2K and leaving 23,282 shares worth $5.86M. The position accounts for 0.61% of the portfolio, ranked #31.
Claro Advisors first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Claro Advisors held 23,282 shares of AbbVie worth $5.86M as of Q2 2026.
- Claro Advisors sold 108 AbbVie shares in Q2 2026, an estimated $23.2K.
- AbbVie made up 0.61% of Claro Advisors's portfolio in Q2 2026, its #31 holding.
- Claro Advisors first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Claro Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.